“I have two copies of the Alzheimer’s gene”: Why tracking my data almost destroyed my mind

“What makes Alzheimer’s uniquely terrifying: you don’t just die; you lose yourself first.” Kevin Tran does not ease you into the subject. There is no softened language, no genteel detour through the usual vocabulary of ageing well.

There is only the horror he cannot shake: “Your loved ones watch you disappear.” Then the line that follows, cruel in its honesty and therefore impossible to ignore: “That scares me more than death itself.”

This is the tension that defines how Tran thinks about brain health and how he has built The Phoenix Community, a science-driven platform for APOE4 carriers that combines personalised tracking, peer support, expert sessions, and experimental protocols for those trying to lower their Alzheimer’s risk.

Tran, a PharmD and APOE4/4 carrier himself, founded it around a brutal premise: for many people at high genetic risk, medicine still offers very little before symptoms arrive. 

“I found out I carry two copies about a year and a half ago,” he says. “Since then, I’ve acted aggressively: my ApoB dropped 39 per cent, my VO₂ max rose 31 per cent, and my body fat dropped 43 per cent. Not because the genes changed. Because I did.” Still, he does not pretend the fear evaporated once he had numbers to chase. He says the opposite.

After learning he carried APOE4, Tran began leaving “clothing in the wine chiller”, forgetting his Windows password, tripping on stairs. “None of it should have happened. Classic nocebo.”

That, for Tran, is the double bind of modern health data. Know too little, and you drift towards catastrophe in ignorance. Knowing too much without a way to act, and the information curdles into psychological harm. “Don’t track what you’re not willing to change,” he says. “If the result is bad and you won’t act on it, the information will only hurt you.”

It is a severe philosophy, but also a coherent one. He does not worship data for its own sake. He values frameworks, pathways, and behaviour change. “The problem was never the data. It’s data without a framework for action.”

Action over fatalism

Tran rejects the passivity that APOE4 can induce. “Your genes load the gun. But you decide whether you pull the trigger.” It is the kind of line that risks sounding too neat until he fills in the harder parts around it. “We know enough to act on the fundamentals. And doing nothing while waiting for perfect evidence is itself a choice, with consequences.”

The fundamentals, as he describes them, are almost offensively unglamorous. “This 80/20 will never be pills. Will never be one magic compound. It comes from the most boring, unsexy interventions: Proper diet, proper exercise, proper sleep, stress reduction, and limiting toxin exposure.”

He calls these “a definitive ‘no regrets’ move”, while his contempt for the more frantic corners of the longevity economy is unmistakable. “The longevity space bombards people with 50 interventions simultaneously. My philosophy: lock in three to five high-impact fundamentals first. Then layer.”

What makes Tran interesting, though, is that he is not merely preaching discipline. He is trying to build an infrastructure around it. “Personalised medicine has traditionally been top-down: your doctor prescribes, you comply. We’re building the opposite.”

In Phoenix, he says, members run “structured N=1 experiments”, share data, compare outcomes and generate insights at the level of genotype. “That’s the leap from support community to research infrastructure.” He believes the future will belong less to universal longevity platforms than to “specialised communities generating evidence for their specific biology”.

Urgency in uncertainty

His impatience with traditional systems runs through the interview. “When I went to see neurologists after my diagnosis, every single one said the same thing: ‘Come back in 30 years when you have symptoms.’ No one mentioned prevention.”

It explains why he thinks private communities and founders will matter more, not less, as cognitive decline becomes a central burden of ageing societies. “Traditional healthcare captures snapshots. We track continuously, and we know not just what moved, but why it moved.”

Tran is persuasive because he does not hide the uncertainty. He stares at it. Alzheimer’s, he says, remains the hardest frontier because “the underlying disease mechanism remains largely unknown.” Yet, his response to uncertainty is not resignation. It is structured urgency. “‘Waiting for more evidence’ is not a neutral position. It’s a decision to let the window close.”

That is where Tran leaves you: in a place without comfort, but not without instruction. He does not offer optimism in the soft, marketable sense. He offers something harsher and more useful. Refuse the story that risk is destiny merely because the system has not yet learned how to help.